Behavioral effects of a new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man.
D000284:Administration, Oral; D001714:Bipolar Disorder / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors*; D004341:Drug Evaluation; D005669:Fusaric Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D010848:Picolinic Acids / Q000627:therapeutic use*
D010848:Picolinic Acids; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D004299:Dopamine beta-Hydroxylase; D005669:Fusaric Acid; D006719:Homovanillic Acid